Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 6, 2007, Pages 858-866

  Leitner, J M ^a   Jilma, B ^a   Mayr, F B ^a   Cardona, F ^a   Spiel, A O ^a   Firbas, C ^a   Rathgen, K ^b   Stahle H ^b   Schuhly U ^b   Graefe Mody, E U ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIBT 986; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING INHIBITOR; LIPOPOLYSACCHARIDE; PLACEBO; PROTHROMBIN A; PROTHROMBIN A INHIBITOR; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; ENDOTOXEMIA; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INFLAMMATION; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; THROMBOCYTE ACTIVATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTOXEMIA; FACTOR XA; FIBRINOLYTIC AGENTS; HALF-LIFE; HISTORY, 15TH CENTURY; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; METABOLIC CLEARANCE RATE; PARTIAL THROMBOPLASTIN TIME; PLATELET ACTIVATION; PROSPECTIVE STUDIES; PROTHROMBIN;

EID: 34249004639     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100153     Document Type: Article

References (42)

1. Ruef, J. & Katus, H.A. New antithrombotic drugs on the horizon. Expert Opin. Investig. Drugs 12, 781-797 (2003).
2. Visser, L.E. et al. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin. Pharmacol. Ther. 71, 496-502 (2002).
3. Morin, S. et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. 75, 403-414 (2004).
4. Gustafsson, D. & Elg, M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res. 109(Suppl 1): S9-S15 (2003).
5. Penning-van Beest, F.J., van Meegen, E., Rosendaal, F.R. & Stricker, B.H. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin. Pharmacol. Ther. 69, 451-457 (2001).
6. Ansell, J. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 204S-233S (2004).
7. Yusuf, S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295, 1519-1530 (2006).
8. Robson, R., White, H., Aylward, P. & Frampton, C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin. Pharmacol. Ther. 71, 433-439 (2002).
9. Eriksson, B.I. et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost. 2, 1573-1580 (2004).
10. Eriksson, B.I. et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3, 103-111 (2005).
11. Graefe-Mody, E.U. et al. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J. Thromb. Haemost. 4, 1502-1509 (2006).
12. Fiuza, C. & Suffredini, A.F. Human models of innate immunity: local and systemic inflammatory responses. J. Endotoxin. Res. 7: 385-388 (2001) (Review).
13. Martich, G.D., Boujoukos, A.J. & Suffredini, A.F. Response of man to endotoxin. Immunobiology 187, 403-416 (1993).
14. Poloyac, S.M., Tosheva, R.T., Gardner, B.M., Shedlofsky, S.I. & Blouin, R.A. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Clin. Pharmacol. Ther. 66, 554-562 (1999).
15. Jilma, B. et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am. J. Respir. Crit. Care Med. 159, 857-863 (1999).
16. Mayr, F. & Jilma, B. Coagulation interventions in experimental human endotoxemia. Transl. Res. 148, 263-271 (2006).
17. Aras, O. et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 103, 4545-4553 (2004).
18. Derhaschnig, U. et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102, 2093-2098 (2003).
19. Pernerstorfer, T. et al. Heparin blunts endotoxin-induced coagulation activation. Circulation 100, 2485-2490 (1999).
20. Jilma, B. et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin. Pharmacol. Ther. 72, 403-410 (2002).
21. de Jonge, E. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95, 1124-1129 (2000).
22. Pernerstorfer, T. et al. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin. Pharmacol. Ther. 66, 51-57 (1999).
23. Hollenstein, U. et al. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clin. Pharmacol. Ther. 71, 368-374 (2002).
24. Hollenstein, U.M. et al. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J. Infect. Dis. 186, 1270-1276 (2002).
25. Pernerstorfer, T. et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 95, 1729-1734 (2000).
26. Kruithof, E.K., Agay, D., Mestries, J.C., Gascon, M.P. & Ythier, A. The effect of factor Xa/phospholipid infusion on the acute phase response in baboons. Thromb. Haemost. 77, 308-311 (1997).
27. Szaba, F.M. & Smiley, S.T. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99, 1053-1059 (2002).
28. Wienen, W., Schurer, J., Priepke, H., Ries, U.J. & Colbatzky, F. Anticoagulant, anti-inflammatory and organoprotective effects of BIBT 986, a novel dual inhibitor of thrombin and factor Xa, on LPS-induced disseminated intravascular coagulation and septicemia in the rat. J Throm. Haemost. 3(Suppl.1): Abstr. P1702 (2005).
29. Franco, R.F. et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 96, 554-559 (2000).
30. Homoncik, M. et al. Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation. Thromb. Res. 108, 91-95 (2002).
31. Jilma, B. et al. The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia. Blood 105, 2380-2383 (2005).
32. Frossard, M. et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110, 1392-1397 (2004).
33. Derhaschnig, U. et al. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit. Care Med. 32, 1136-1140 (2004).
34. Homoncik, M. et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br. J. Haematol. 111, 1250-1252 (2000).
35. Mayr, F.B. et al. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am. J. Respir. Crit. Care Med. 171, 354-360 (2005).
36. van der Poll, T. et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 89, 3727-3734 (1997).
37. Spiel, A.O. et al. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thromb. Haemost. 94, 1148-1156 (2005).
38. Leitner, J.M. et al. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin. Pharmacol. Ther. 79, 23-34 (2006).
39. Fenyvesi, T., Jorg, I. & Harenberg, J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin. Thromb. Hemost. 28, 361-368 (2002).
40. Kher, A., Gouin, I. & Samama, M.M. Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time. Ann. Biol. Clin. (Paris) 58, 575-579 (2000).
41. Derhaschnig, U. et al. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit. Care Med. 31, 1108-1112 (2003).
42. Jilma-Stohlawetz, P. et al. Effects of anticoagulation on thrombopoietin release during endotoxemia. J. Lab. Clin. Med. 137, 64-69 (2001).